Does insurance cover Augmentin in the United States? The answer depends on the specific health plan, its prescription drug formulary and the exact product being prescribed. Original branded Augmentin contains amoxicillin and clavulanate potassium, while FDA-approved generic versions are listed under the established ingredient names. A commercial plan may treat the original brand and a corresponding generic differently, including different formulary tiers, cost-sharing rules or restrictions. Coverage for one conventional tablet strength does not automatically establish coverage for every tablet, chewable or oral suspension presentation.
Commercial prescription coverage is determined by the terms of the patient's actual plan rather than the general name of the insurance company. Employer-sponsored plans, individual plans and Marketplace plans can use different prescription drug lists, pharmacy networks and benefit arrangements. A formulary may identify generic amoxicillin/clavulanate as a covered product while applying separate requirements to original brand Augmentin. Prior authorization, step therapy or quantity limits may also appear when specified by the plan. These restrictions should not be assumed to apply universally; they must be checked against current plan documents and pharmacy benefit information.
This guide explains how to locate the relevant formulary entry, verify the correct combination strength and dosage form, understand brand restrictions and check a network pharmacy. It also describes how a clinician may request a coverage exception when the plan's rules permit one. No insurance approval, copay, stock or prescription outcome is guaranteed. The brand Augmentin cost guide covers cash-price factors, while generic amoxicillin/clavulanate pricing addresses costs outside a plan-specific coverage determination.
U.S. commercial health insurance plans commonly administer outpatient prescription benefits using a formulary, also called a prescription drug list. This list identifies covered medicines and may describe cost-sharing levels or utilization-management requirements. A medicine's FDA approval status is not the same as its coverage status under a particular commercial plan.
Original brand Augmentin and generic amoxicillin/clavulanate may occupy different positions in a plan's drug list. Some formularies favor particular approved generic products, while brand-name products may have separate cost-sharing conditions or require an exception when they are not routinely covered. The actual treatment of either category depends on the individual plan.
Coverage can also depend on the exact dosage form and strength. Conventional immediate-release tablets, chewable tablets and oral suspension products have distinct FDA-labeled characteristics. Augmentin XR and Augmentin ES-600 are separately labeled products with their own formulation requirements. A broad formulary search result for amoxicillin/clavulanate should not be interpreted as coverage for all these presentations.
Even when a product appears on the formulary, the plan may apply prior authorization, quantity limitations, applicable pharmacy-network requirements or specific cost sharing. These conditions are not proof that a prescription is clinically appropriate, and a prescription from a clinician does not by itself guarantee an approved insurance claim.
The most reliable starting point is the member-specific prescription benefit information for the applicable plan year. HealthCare.gov advises Marketplace members to review their insurer's covered-drug list and Summary of Benefits and Coverage or contact the insurer directly. The same principle of checking the exact benefit applies to other commercial plans.
This page addresses commercial insurance administration and product identification. Medicare-specific prescription benefit rules belong in the separate Augmentin Medicare coverage guide.
A formulary search should begin with the correct insurance plan rather than a general insurer name. Insurers may administer several employer, individual or Marketplace products, each with different prescription drug lists. A publicly available formulary that belongs to another plan or coverage year may not describe the member's actual benefits.
The search should include both Augmentin and the generic ingredient names amoxicillin and clavulanate potassium. The formulation may be listed under the brand, the established generic name or a standardized drug classification. A search for plain amoxicillin alone is insufficient because it does not establish coverage for the two-ingredient combination.
After finding a potential entry, the next step is to identify the dosage form and complete strength pair. An entry for generic 875 mg/125 mg conventional tablets does not automatically establish coverage for standard suspension, chewable tablets, ES-600 or XR. The prescribed quantity should also be checked against any benefit limits.
The formulary may display a tier or cost-sharing category and abbreviations indicating utilization management. Examples include prior authorization, step therapy and quantity limits. Insurers may use different terminology or codes, so the plan's explanatory legend should be read alongside the drug entry.
A formulary lookup is a preliminary coverage check rather than a final adjudication. The actual prescription claim may depend on the member's eligibility, benefit phase, pharmacy network and the product submitted for dispensing.
The FDA's Augmentin product approval guide helps establish regulatory product identity. The insurer's active formulary, however, is the controlling reference for plan-specific coverage questions.
| Lookup step | What to verify | Why it matters |
|---|---|---|
| Insurance plan | Exact plan name, coverage type and effective year | Different plans from the same insurer may use different drug lists. |
| Drug name | Augmentin and amoxicillin/clavulanate | Brand and generic entries may appear separately. |
| Dosage form | Conventional tablet, chewable tablet, oral suspension or separately labeled formulation | Coverage of one form does not confirm coverage of another. |
| Strength | Both amoxicillin and clavulanic-acid amounts | Distinguishes the prescribed product from other combination strengths. |
| Formulary status | Covered, excluded, nonformulary or another plan-defined category | Identifies the applicable benefit classification. |
| Coverage restrictions | Prior authorization, step therapy or quantity limits, if present | Shows whether further plan review may be required. |
| Network pharmacy | A participating pharmacy under the member's specific benefit | Pharmacy participation may affect claim processing and cost sharing. |
The original Augmentin brand and approved generic amoxicillin/clavulanate products may have different formulary treatment. A commercial plan may place an approved generic on a preferred tier while applying a higher cost-sharing level or a coverage restriction to the corresponding brand. This is a possible plan design, not a universal rule for every insurer.
Generic substitution is governed by product-specific FDA approval and applicable pharmacy laws. The FDA Orange Book identifies approved medicines and therapeutic-equivalence evaluations. Those records can help distinguish eligible generic products, but they do not establish whether a commercial insurance plan covers a particular manufacturer or NDC.
A plan may also use preferred generic products or pharmacy-benefit processing rules that affect the item accepted at the point of sale. A patient-facing package may name a labeler or repackager different from the ANDA holder. These differences should be reconciled through the actual product identification and pharmacy benefit response rather than treated as automatic coverage denials.
A prescription written for original brand Augmentin may encounter different coverage conditions from one permitting a corresponding generic. If the insurer does not routinely cover the brand, the prescriber may be able to request a formulary exception under the plan's rules. An exception is not automatic and generally requires appropriate supporting information.
The brand-versus-generic distinction must preserve the correct strength and dosage form. A generic conventional tablet is not an automatic substitute for Augmentin XR, and standard oral suspension is not freely interchangeable with ES-600. The plan's formulary should be evaluated for the actual prescribed product.
For product and regulatory context, see the Augmentin vs generic comparison and generic manufacturer records. Neither page replaces the member's formulary or the pharmacy's benefit verification.
| Coverage question | Original brand Augmentin | Approved generic amoxicillin/clavulanate |
|---|---|---|
| Product listing | May appear under the proprietary Augmentin name | May appear under the established ingredient names. |
| Formulary tier | Depends on the individual commercial plan | Depends on the individual commercial plan. |
| Prior authorization | Check the exact brand entry and applicable restrictions | Check the exact generic entry; do not assume unrestricted coverage. |
| Coverage exception | May be relevant when the requested brand is not routinely covered | May be relevant for a restricted or nonformulary generic product. |
| Pharmacy claim | Must identify the actual brand product and applicable plan rules | Must identify an eligible approved generic product and applicable plan rules. |
The phrase amoxicillin/clavulanate covers multiple prescription product types. Commercial insurance formularies can distinguish dosage forms, concentrations and release characteristics. A broad covered-drug entry is therefore not enough to confirm the benefit for every Augmentin-related product.
Conventional immediate-release tablets are commonly identified by the full strength pairs 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. A formulary entry or pharmacy claim must correspond to the prescribed pair. A benefit determination for one strength should not be extended automatically to another.
Chewable tablets have separate strength pairs, including 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg. Standard oral suspensions use corresponding concentration pairs per 5 mL after reconstitution. Their benefit status and quantity rules should be checked separately from conventional tablets.
Augmentin XR is an extended-release tablet containing 1,000 mg/62.5 mg per tablet and has distinct FDA labeling. Augmentin ES-600 is a pediatric suspension containing 600 mg/42.9 mg per 5 mL. Their formulation and substitution restrictions mean that a regular Augmentin formulary listing does not establish that the insurer will cover either specialized product.
The pharmacy should verify the prescribed dosage form, complete strength and actual product identifier when submitting a claim. If the plan's entry is ambiguous, the insurer or pharmacy benefit administrator can clarify which presentation is covered and whether additional review is required.
Formulation-specific product information is available in the standard tablet guide, chewable guide, oral suspension guide, XR guide and ES-600 guide.
| Product category | FDA-labeled identification | Insurance verification requirement |
|---|---|---|
| Conventional tablets | 250/125, 500/125 and 875/125 mg | Check the exact immediate-release tablet strength. |
| Chewable tablets | 125/31.25, 200/28.5, 250/62.5 and 400/57 mg per tablet | Confirm a chewable-specific formulary entry and quantity. |
| Standard oral suspension | 125/31.25, 200/28.5, 250/62.5 and 400/57 mg per 5 mL | Confirm concentration and the final dispensed liquid volume. |
| Augmentin XR | 1,000/62.5 mg extended-release tablet | Verify XR specifically; conventional tablet coverage is insufficient. |
| Augmentin ES-600 | 600/42.9 mg per 5 mL pediatric suspension | Verify ES-600 specifically; standard liquid coverage is insufficient. |
A medicine described as nonformulary is not routinely included in the plan's covered drug list under the stated benefit conditions. The term does not by itself establish that the medicine is unavailable commercially or inappropriate clinically. It describes a coverage classification, which must be interpreted according to the specific plan.
Commercial plans may provide a process for requesting an exception when a prescribed medicine is not ordinarily covered or when a restriction presents a clinically relevant issue. HealthCare.gov explains that Marketplace plans have drug exception processes and that a prescriber may need to provide information about why the requested medicine is appropriate.
For original brand Augmentin, an exception may involve establishing why the requested brand is being considered instead of a formulary-listed generic. The necessary justification is a clinical and coverage question for the prescriber and insurer, not a reason for a patient to choose a brand or reject a generic independently.
An exception request should correctly identify the medicine, dosage form, strength and any applicable restriction. A request for conventional branded tablets is not automatically a request for Augmentin XR or ES-600. Likewise, an insurer's response to one strength does not necessarily describe another.
Approval of an exception is not guaranteed. If a request is denied, the member may be able to use the plan's internal appeal process and, when applicable, further review procedures. The precise steps and deadlines depend on the plan and relevant insurance rules.
The purpose of the process is to obtain an appropriate coverage determination for the medicine requested by the prescriber. It should not be represented as a method of bypassing the need for medical evaluation, prescription validity or pharmaceutical substitution safeguards.
A covered prescription may have different payment or processing conditions depending on the dispensing pharmacy. Commercial health plans commonly establish pharmacy networks, and a member's in-network pharmacy may differ from the pharmacy that offers the lowest advertised cash price.
HealthCare.gov advises members to confirm which pharmacies are within their particular plan network. Insurers may also maintain preferred network arrangements or different benefit rules for certain pharmacy categories. Network participation should therefore be checked for the member's exact plan rather than inferred from a retailer's general relationship with an insurance company.
The pharmacy must process the actual prescribed product using the relevant benefit information. A claim can be affected by the product's NDC, dosage form, strength, quantity and member eligibility. A listed formulary drug does not guarantee that every package offered by every pharmacy will produce the same transaction result.
The pharmacy's current stock is a separate issue. An insurer may cover a product that a particular pharmacy does not currently have available, while an available product may not be covered under the member's benefit. Insurance approval and product availability should not be conflated.
If a preferred pharmacy cannot supply a particular branded Augmentin product, the member can ask about other participating locations and have the prescriber or pharmacist review any product change that may be necessary. Patients should not independently replace XR, ES-600 or other noninterchangeable formulations.
The Augmentin online pharmacy guide addresses pharmacy-service verification. This page focuses on benefit networks rather than promoting any specific retailer or promising delivery.
Coverage and out-of-pocket cost are related but separate questions. A formulary-listed Augmentin or generic amoxicillin/clavulanate product may still involve a patient payment. The amount can depend on the product's assigned tier, copay, coinsurance, deductible status and pharmacy network.
A copay is generally a fixed patient payment under the relevant benefit rules, while coinsurance is commonly a percentage-based share of an eligible charge. When a deductible has not been met, the patient may owe a different amount from what would apply later in the benefit period. No fixed Augmentin copay can be inferred without the actual plan.
A generic drug may be assigned a different tier from the original brand, but that distinction varies by formulary. A brand-name exception can also be associated with particular cost-sharing rules. Approval for a brand exception does not necessarily mean the patient will pay the same amount as for a preferred generic.
A cash purchase or an ordinary prescription discount-card transaction is generally separate from a claim paid through insurance. Such discounts are not automatically combined with copays, and payments outside a plan may be treated differently for deductible or out-of-pocket accounting.
The Augmentin discount cards guide explains pharmacy coupon processing, while Augmentin without insurance addresses cash-pay healthcare expenses. This section is limited to the interpretation of commercial prescription benefit cost sharing.
| Benefit term | Meaning | Question for the plan |
|---|---|---|
| Formulary tier | Drug classification used for coverage and cost sharing | Which tier applies to the exact Augmentin or generic product? |
| Copay | A fixed member payment under applicable benefit terms | What copay applies at the intended network pharmacy? |
| Coinsurance | A percentage-based member payment | Which eligible cost is used to calculate the percentage? |
| Deductible | Plan-defined amount that may affect payment before certain benefits apply | How does the member's current deductible status affect the claim? |
| Brand exception | A request for coverage outside ordinary formulary rules | If granted, which cost-sharing category applies? |
| Network status | The pharmacy's participation in the member's benefit network | Does the selected pharmacy qualify for the relevant benefit terms? |
A pharmacy claim rejection does not always mean that the prescribed medicine is categorically excluded from coverage. The rejection may relate to a nonformulary product, prior authorization requirement, quantity limit, pharmacy network status, member eligibility or incorrect product information. The specific claim response should be reviewed before drawing conclusions.
The pharmacist can confirm that the claim identifies the correct active-ingredient combination, strength, dosage form, quantity and product record. Errors involving brand versus generic selection or an incorrectly entered quantity may need correction without changing the prescription.
If the claim identifies a genuine coverage restriction, the member or prescriber can contact the insurer to understand the applicable rule. Where an exception or prior authorization is available, the plan can describe the necessary submission process.
A rejected claim should not prompt a patient to purchase a different formulation or combine tablet strengths independently. The clinician and pharmacist must assess whether any proposed change is appropriate, particularly for Augmentin XR and ES-600.
HealthCare.gov describes drug exception and appeals processes for Marketplace coverage. Other commercial plans may have different internal procedures, which should be checked through the plan's member documents. No appeal outcome or processing time is guaranteed.
A pharmacy may also offer a separate cash quotation if the insurance claim cannot be processed, but that quotation does not resolve the underlying coverage question. The two payment possibilities should be kept distinct.
The most efficient way to verify Augmentin coverage is to begin with the member's actual insurance plan and existing prescription. The plan year, formulary, exact medicine, dosage form, strength and quantity should be identified before checking tier placement or restrictions.
For the combination medicine, both amoxicillin and clavulanic-acid quantities must be preserved. A formulary entry for plain amoxicillin is not sufficient. Similarly, coverage of generic conventional tablets does not automatically answer questions about original brand Augmentin, chewables, suspension, XR or ES-600.
After identifying the correct formulary entry, the next step is to check whether prior authorization, step therapy, quantity limits or other stated conditions apply. When restrictions are present, the insurer can clarify its rules and whether the prescriber may request an exception.
The member should then verify that the intended dispensing pharmacy is within the relevant network and request a plan-specific cost estimate. The pharmacy can confirm the actual product and submit the prescription claim when appropriate.
Coverage records should be reviewed again if the plan year changes, the prescription product changes or the insurer announces a formulary update. An earlier claim approval or online listing does not guarantee that future transactions will have identical terms.
This checklist is designed for commercial plans. Medicare prescription coverage is governed by separate program rules and should be evaluated through the Augmentin Medicare coverage guide.
Coverage depends on the specific commercial insurance plan, the exact Augmentin product and its formulary rules. Original brand Augmentin and generic amoxicillin/clavulanate may be treated differently. The insurer or pharmacy benefit administrator must verify coverage for the member's actual plan.
Generic amoxicillin/clavulanate may be included in a commercial plan's prescription drug formulary, but coverage is not universal. The dosage form, strength, quantity, pharmacy network and applicable restrictions must be checked against the member's plan.
Not necessarily. A plan may list a generic as covered while placing separate restrictions on original brand Augmentin. The exact brand entry and any available exception process should be checked with the insurer.
Locate the prescription drug list for the correct insurer, plan and coverage year. Search both Augmentin and amoxicillin/clavulanate, then verify the exact dosage form, complete strength pair, formulary tier and any prior authorization or quantity requirements.
Nonformulary generally means the medicine is not routinely covered under the plan's standard drug list. The plan may offer an exception process, depending on its rules. The prescriber or insurer can explain the applicable requirements, and approval is not guaranteed.
That depends on the specific commercial plan and product. Some plans apply prior authorization to selected prescription medicines, while others do not. A general insurer name or product listing is not enough to establish whether a particular Augmentin prescription requires approval.
A commercial plan may favor an approved generic through formulary placement or coverage restrictions on the brand. Any substitution must comply with the prescription, FDA product requirements and applicable pharmacy laws. Patients should not make the change independently.
Some commercial plans allow prescribers to request an exception to ordinary formulary rules, including for a nonformulary brand. The required clinical justification and submission procedure depend on the plan. An exception request does not guarantee coverage.
Coverage of conventional 875 mg/125 mg tablets depends on the plan's exact formulary entry and the prescribed product. The insurer may distinguish original branded tablets from generic amoxicillin/clavulanate and may apply quantity or other benefit conditions.
Chewable products may be evaluated separately from conventional tablets because they have distinct dosage forms and strength pairs. The exact chewable product should be checked against the member's formulary instead of assuming tablet coverage applies.
Coverage depends on the plan, original brand or generic status, concentration and dispensed quantity. An entry for conventional tablets does not necessarily establish coverage for oral suspension.
Not automatically. Augmentin XR is a distinct extended-release product containing 1,000 mg/62.5 mg per tablet. Its FDA labeling and formulation differ from conventional Augmentin tablets, so its current formulary status must be verified separately.
Coverage is plan-specific. ES-600 is a separately labeled pediatric suspension containing 600 mg/42.9 mg per 5 mL. Coverage of ordinary amoxicillin/clavulanate liquid does not establish coverage for ES-600.
A formulary tier is a plan-defined category used to organize prescription drugs and determine applicable benefit terms or cost sharing. The tier for Augmentin can differ from the tier for generic amoxicillin/clavulanate and must be checked under the member's actual plan.
Not necessarily. A commercial plan may distinguish in-network, out-of-network or preferred pharmacies, and the patient's deductible or coinsurance status may also affect payment. The actual amount should be confirmed for the chosen pharmacy.
Ordinary prescription discount cards generally operate as an alternative to insurance payment rather than an additional discount applied to the same claim. The pharmacy should explain the eligible payment options and any effects on insurance cost accounting.
Ask the pharmacist or insurer for the specific rejection reason. It may concern the product, formulary status, quantity, prior authorization, network pharmacy or member eligibility. If a coverage restriction applies, the prescriber may be able to review the plan's exception or appeal process.
No. A valid prescription establishes the prescribed medicine but does not guarantee that a commercial insurer will pay for it. The plan must evaluate the actual product and applicable benefit rules, and the dispensing pharmacy must separately confirm supply.